|
|
| (36 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{Hepatitis C}} | | __NOTOC__ |
| {{CMG}}; {{AOEIC}} {{VK}}, [[User:Ujjwal Rastogi|Ujjwal Rastogi, MBBS]] [mailto:urastogi@perfuse.org]
| | {{HIV coinfection with hepatitis c}} |
| ==Overview==
| | '''For main chapter on AIDS, click [[AIDS|here]]''' |
| HIV has been an important and familiar health and social crisis for two decades. Less familiar, but also important, is HCV infection. In HIV–HCV co-infected patients, the Hepatitis C (HCV) viral load is higher than in HCV-mono-infected patients in both the plasma and liver tissue.
| |
|
| |
|
| '''Similarity between Hepatitis C with HIV:''' | | '''For main chapter on HIV, click [[HIV|here]]''' |
| These two viruses are similar in a number of ways, and infection with both is a serious problem. Both HCV and HIV are transmitted by
| | |
| exposure to infected blood. About one-quarter of the people infected with HIV also have HCV.
| | '''For main chapter on Hepatitis C, click [[Hepatitis C|here]]''' |
|
| |
|
| ==Cause of Co-infection==
| | {{CMG}}; {{AOEIC}} {{VK}} |
| Patients who are HIV-positive are commonly co-infected with HCV due to the following:
| |
| *Shared routes of transmission.
| |
| *Percutaneous exposure to blood.
| |
| *Sexual intercourse.
| |
| *From a mother to her infant.
| |
|
| |
|
| ==Pathophysiology== | | ==[[HIV coinfection with hepatitis c overview|Overview]]== |
| '''HIV’s effect on Hepatitis C:''' Studies have shown that HIV infection in a person who is also infected with HCV results in higher levels of HCV in the blood, more rapid progression to HCV-related liver disease, and increased risk for cirrhosis and liver cancer. As a result, HCV is now regarded as an opportunistic infection in people with HIV infection, although it is not considered an AIDS-defining illness.
| |
|
| |
|
| '''HCV’s effect on HIV:''' Some research suggests that infection with genotype 1 HCV is associated with more rapid progression to AIDS
| | ==[[HIV coinfection with hepatitis c pathophysiology|Pathophysiology]]== |
| or death, although this is still controversial. Most people with HCV infection in the U.S. have genotype 1. Genotypes 2 and 3 are more common in Europe.) Some evidence also indicates that HCV is associated with impaired CD4+ T cell recovery during antiretroviral therapy.
| |
|
| |
|
| ==Epidemiology== | | ==[[HIV coinfection with hepatitis c causes|Causes]]== |
| The majority of coinfected people are injection drug user (IDUs). HCV is acquired relatively soon after individuals begin injecting drugs. Within 5 years of beginning to inject, 50% to 80% of IDUs are infected with HCV. As a result, many IDUs who become infected with HIV are already infected with HCV. It is estimated that 50% to 90% of IDUs.
| |
|
| |
|
| Between 1996 and 2000, more than 80% of the patients admitted to a large HIV/AIDS care center in Madrid, Spain, were IDUs. The proportion of these patients who were admitted because of liver failure almost doubled, from 9% to 16%.
| | ==[[HIV coinfection with hepatitis c differential diagnosis|Differentiating HIV coinfection with hepatitis c from other Diseases]]== |
|
| |
|
| ==Natural History== | | ==[[HIV coinfection with hepatitis c epidemiology and demographics|Epidemiology and Demographics]]== |
| The effect of HCV on the natural history of HIV remains inconclusive due to contradictory studies documenting no effect, while others show an increase to an AIDS defining illness or death. The morbidity and mortality caused by HCV has increased since the inception of highly active antiretroviral therapy (HAART) because HIV patients are living longer from potent antiretroviral therapies and prophylaxis of traditional opportunistic infections. Infection with HCV can be asymptomatic, self-limiting, or progress to [[cirrhosis]] or [[Hepatocellular carcinoma|cancer]].
| |
| ===Complications===
| |
|
| |
|
| End-stage liver disease is now the cause of death for 45% of HIV-infected patients in this hospital. HCV infection was the cause of the liver disease in nearly three-quarters of the HIV patients who were admitted or died during the course of the study.<ref name="pmid11709090">{{cite journal |author=Martín-Carbonero L, Soriano V, Valencia E, García-Samaniego J, López M, González-Lahoz J |title=Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients |journal=AIDS Res. Hum. Retroviruses |volume=17 |issue=16 |pages=1467–71 |year=2001 |month=November |pmid=11709090 |doi=10.1089/08892220152644160 |url=http://dx.doi.org/10.1089/08892220152644160 |accessdate=2012-03-27}}</ref>
| | ==[[HIV coinfection with hepatitis c risk factors|Risk Factors]]== |
|
| |
|
| ==Treatment== | | ==[[HIV coinfection with hepatitis c natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
| The '''primary objective''' of HCV therapy is permanent eradication of the virus. The '''secondary''' potential benefit of eradication is a reduction in the risk of liver failure and liver cancer.
| |
|
| |
|
| ===Role & Importance of treatment=== | | ==Diagnosis== |
|
| |
|
| The introduction in the mid-1990s of highly active antiretroviral therapy (HAART) for HIV has caused a sharp drop in the number of deaths from AIDS. This means that people with HIV are living longer. Therefore, if they are coinfected, the complications from
| | [[HIV coinfection with hepatitis c history and symptoms|History and Symptoms]] | [[HIV coinfection with hepatitis c physical examination|Physical Examination]] | [[HIV coinfection with hepatitis c laboratory findings|Laboratory Findings]] |
| HCV have more time to develop. These complications (cirrhosis, liver cancer, end-stage liver disease) generally develop over 20-30 years.
| |
|
| |
|
| Liver disease from HCV is now the leading non-AIDS cause of death in the U.S. in coinfected individuals with HIV. Treatment for each disease is complicated, expensive, and has side effects. This poses difficult issues for patients who are living with both HIV and HCV. Finally, coinfection is important because it has a disproportionate impact on certain communities, including those in prison and jail and communities of color.
| | ==Treatment== |
| | |
| ===Regimen===
| |
| The Food and Drug Administration (FDA) has approved two antiviral drugs for the treatment of chronic hepatitis C:
| |
| * [[Alpha interferon]] or an improved form of interferon, called [[Pegylated interferon alpha|pegylated interferon]]
| |
| * [[Ribavirin]]
| |
| | |
| Interferon is given alone or in combination with ribavirin usually for a 12-month period to patients with chronic hepatitis C who are at greatest risk of developing serious liver disease.
| |
| | |
| ===='''Interferon'''====
| |
| '''Mechanism of action:''' [[Interferon]]s bind to specific cell surface receptors of virus-infected cells, which induces a complex cascade of protein-protein interactions and a rapid activation of gene transcription. The antiviral effects of interferons are mediated through inhibition of viral penetration or uncoating, inhibiting viral replication or translation of viral proteins, and/or viral assembly and release.
| |
| | |
| '''Difference between peginterferon and interferon:''' The difference between peginterferon and interferon is the addition of a [[polyethylene glycol]] (PEG) [[polymer]]. The addition of PEG decreases plasma clearance considerably, protects the molecule from proteolytic degradation and reduces its immunogenicity.
| |
| ====Ribavirin====
| |
| | |
| ===General recommendations===
| |
| | |
| '''Coinfected IDUs should do the following:'''
| |
| *Stop injecting drugs.
| |
| #Get into substance abuse treatment.
| |
| #Stay in treatment.
| |
| #If they are not able to stop, they should use sterile syringes and equipment and not share drug solution, syringes, or preparation equipment (needles, drug solution containers, water, cotton filters).
| |
| *Stop drinking alcoholic beverages; If they are not able to stop, they should limit drinking because alcohol contributes to liver damage; when appropriate, they should be referred to alcohol treatment and relapse-prevention programs.
| |
| *Practice safer personal care and sexual behaviors; Not sharing toothbrushes and razors, using condoms consistently, limiting the number of sex partners, getting treatment for sexually transmitted diseases.
| |
| * Be immunized against hepatitis A and hepatitis B, unless they are already immune from past exposure.
| |
| * Regular check-ups to monitor overall health and status of liver disease; coinfected individuals on HAART may be at increased risk of liver toxicity and should be closely monitored.
| |
| ===Treatment issues for coinfected individuals===
| |
| | |
| * Treatment for each of these diseases involves long-term therapy with multiple powerful drugs.
| |
| * Adherence to either treatment regimen is critically important to their success, and for HIV, to prevent resistance from developing.
| |
| *These issues are compounded for individuals who are living with both treatment regimens.
| |
| *Treatment for either disease also has side effects, which should be closely monitored.
| |
| *Therapy with interferon alone appears to be reasonably well tolerated in co-infected patients; However, combination therapy (with ribavirin) may result in severe complications, including death. Until further safety data are available, combination therapy should be used with caution.
| |
| *Another factor to consider is that effectiveness of treatment may be influenced by factors such as the person’s age, how healthy he or she is at the beginning of therapy, the degree of existing liver disease, the person’s CD4 count, and the extent of any other HIV-related illnesses.
| |
| | |
| ==Prevention==
| |
| There is no vaccine for hepatitis C. The best way to prevent hepatitis C infection is to never inject drugs, or to stop injecting drugs if you currently do so by getting into and staying in a drug treatment program.
| |
| | |
| If injecting drugs is continued, new sterile syringes must be used and once used or share syringes, needles, water, or other drug preparation equipment should be completely avoided.
| |
|
| |
|
| ==Recommendations for Diagnosis and Treatment of Persons with HIV Coinfection: AASLD Practice Guidelines 2009<ref name="pmid19554546">{{cite journal |author=Swan T, Curry J |title=Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users |journal=[[Hepatology (Baltimore, Md.)]] |volume=50 |issue=1 |pages=323–4; author reply 324–5 |year=2009 |month=July |pmid=19554546 |doi=10.1002/hep.23077 |url=http://dx.doi.org/10.1002/hep.23077 |accessdate=2012-02-21}}</ref>==
| | [[HIV coinfection with hepatitis c medical therapy|Medical Therapy]] | [[HIV coinfection with hepatitis c prevention|Prevention]] | [[HIV coinfection with hepatitis c cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[HIV coinfection with hepatitis c future or investigational therapies|Future or Investigational Therapies]] |
| {{cquote|
| |
| '''1.''' Anti-HCV testing should be performed in all HIV-infected persons ''(Class I, Level B)''.
| |
|
| |
|
| '''2.''' HCV RNA testing should be performed to confirm HCV infection in HIV-infected persons who are positive for anti-HCV, as well as in those who are negative and have evidence of unexplained liver disease ''(Class I, Level B)''.
| | ==Case Studies== |
| | [[HIV coinfection with hepatitis c case study one|Case #1]] |
|
| |
|
| '''3.''' Hepatitis C should be treated in the HIV/HCV co-infected patient in whom the likelihood of serious liver disease and a treatment response are judged to outweigh the risk of morbidity from the adverse effects of therapy ''(Class I, Level A)''.
| | ==Related Chapters== |
|
| |
|
| '''4.''' Initial treatment of hepatitis C in most HIV infected patients should be peginterferon alfa plus ribavirin for 48 weeks at doses recommended for HCV mono-infected patients ''(Class I, Level A)''.
| | * [[Coinfection]] |
| | | * [[AIDS]] |
| '''5.''' When possible, patients receiving [[zidovudine]] (AZT) and especially didanosine (ddI) should be switched to an equivalent antiretroviral agent before beginning therapy with ribavirin ''(Class I, Level C)''.
| | * [[HIV disease]] |
| | | * [[Hepatitis B with HIV coinfection]] |
| '''6.''' HIV-infected patients with decompensated liver disease (CTP Class B or C) should not be treated with peginterferon alfa and ribavirin and may be candidates for liver transplantation ''(Class IIa, Level C)''.}}
| | * [[Tuberculosis and HIV coinfection]] |
| | | * [[HIV and tuberculosis coinfection : drug interaction]] |
| ==References==
| | * [[HIV and pregnancy]] |
| {{reflist|2}}
| | * [[Hepatitis]] |
|
| |
|
| {{WS}} | | {{WS}} |
| Line 102: |
Line 50: |
| [[Category:Hepatitis|C]] | | [[Category:Hepatitis|C]] |
| [[Category:Gastroenterology]] | | [[Category:Gastroenterology]] |
| [[Category:Infectious disease]]
| |
| [[Category:Disease]]
| |
|
| |
| ==References==
| |
| {{reflist|2}}
| |
|
| |
|
| {{WS}}
| |
| {{WH}}
| |
|
| |
| [[Category:Hepatitis|C]]
| |
| [[Category:Gastroenterology]]
| |
| [[Category:Infectious disease]]
| |
| [[Category:Disease]] | | [[Category:Disease]] |